search

1-20 of 29

Save search

Sort by

Sort Order Select

Journal Article

P637 Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA–exposed, advanced therapy–naive, immunomodulator-naive patients with ulcerative colitis: a post hoc analysis of True North

PDF

S Horst and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1211–i1212, https://doi.org/10.1093/ecco-jcc/jjad212.0767

Published: 24 January 2024

Journal Article

P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

PDF

G D'Haens and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1814–i1815, https://doi.org/10.1093/ecco-jcc/jjad212.1139

Published: 24 January 2024

Journal Article

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

PDF

S W Schreiber and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i216–i217, https://doi.org/10.1093/ecco-jcc/jjad212.0118

Published: 24 January 2024

Journal Article

P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis

PDF

B Siegmund and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1461–i1463, https://doi.org/10.1093/ecco-jcc/jjad212.0919

Published: 24 January 2024

Journal Article

P567 Impact of recent thiopurine use on ozanimod safety in patients with ulcerative colitis: a post hoc analysis of the phase 3 True North study

PDF

R Battat and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1100–i1101, https://doi.org/10.1093/ecco-jcc/jjad212.0697

Published: 24 January 2024

Journal Article

DOP16 Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

PDF

C Siegel and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i100–i101, https://doi.org/10.1093/ecco-jcc/jjad212.0056

Published: 24 January 2024

Journal Article

P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling

PDF

S W Schreiber and others

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1067–i1068, https://doi.org/10.1093/ecco-jcc/jjad212.0675

Published: 24 January 2024

Journal Article

DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study

PDF

S Vermeire and others

Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i103–i104, https://doi.org/10.1093/ecco-jcc/jjac190.0079